All In Biotech

Drug Trial Radar · NCT07043725

A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

A Randomized, Open-label, Multicenter, Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus TCbHP in Neoadjuvant Treatment of Breast Cancer With Positive HER2 Expression

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 544 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

544

Planned (sponsor's estimate)

Start

Sep 15, 2025

Primary completion

Sep 2027

Study completion Sep 2029

Sponsor

Sponsor type
Industry
First posted
Jun 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, open, positive drug control, multi center phase III study. Through the evaluation of tpCR, bpCR, ORR, EFS, IDFS, OS, AEs and other indicators, it proves the effectiveness and safety of TQB2102 for injection versus Active Comparator in the neoadjuvant treatment of HER2 positive breast cancer patients. About 544 HER2 positive early or locally advanced breast cancer patients will be randomly assigned to TQB2102 treatment group (test group) or Docetaxel combined with Carboplatin, Trastuzumab, and Pertuzumab (TCbHP) (Active Comparator) in a 1:1 ratio. The subjects in the test group will receive 8 cycles of study drug treatment, and the subjects in the control group will receive 6 cycles of study drug treatment, followed by surgery for breast cancer, and disease recurrence visit and survival visit after surgery.

Conditions

  • HER2-positive Breast Cancer

Interventions

  • TQB2102 for injectionDrug

    TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC)

  • Trastuzumab injection and Pertuzumab Injection and Docetaxel Injection and Carboplatin InjectionDrug

    TCbHP is a commonly used chemotherapy scheme for HER2 positive breast cancer. H represents Trastuzumab injection, P represents Pertuzumab Injection, T represents Docetaxel injection and C represents Carboplatin injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of total physiological complete response (tpCR) evaluated by Independent Review Committee (IRC)Time frame: Up to 26 months after study start

Locations

77 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical University

    Bengbu, Anhui, China · Not yet recruiting

  • Anhui Provincial Cancer Hospital

    Hefei, Anhui, China · Not yet recruiting

  • The First Affiliated Hospital of Wannan Medical University

    Wuhu, Anhui, China · Not yet recruiting

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • The Second Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • The Cancer Hospital Affiliated to Chongqing University, Chongqing Cancer Hospital, Chongqing Cancer Research Institute, and Chongqing Cancer Center

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • The First Hospital Affiliated to Army Medical University

    Chongqing, Chongqing Municipality, China · Not yet recruiting

  • Quanzhou First Hospital

    Quanzhou, Fujian, China · Not yet recruiting

  • The Second Affiliated Hospital of Fujian Medical University

    Quanzhou, Fujian, China · Not yet recruiting

  • Zhongshan Hospital Xiamen university

    Xiamen, Fujian, China · Not yet recruiting

  • ZhangZhou Municipal Hospital of Fujian Province

    Zhangzhou, Fujian, China · Not yet recruiting

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, China · Not yet recruiting

  • Gansu Provincial Academic Institute for Medical Research, Gansu Provincial Cancer Hospital

    Lanzhou, Gansu, China · Not yet recruiting

  • Gansu Wuwei Tumour Hospital

    Wuwei, Gansu, China · Not yet recruiting

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China · Not yet recruiting

  • The Second Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China · Not yet recruiting

  • Meizhou People's Hospital

    Meizhou, Guangdong, China · Not yet recruiting

  • Shantou Central Hospital

    Shantou, Guangdong, China · Not yet recruiting

  • Guigang City People's Hospital

    Guigang, Guangxi, China · Not yet recruiting

  • Guangxi Cancer Institutu (Guangxi Cancer Hospital, Guangxi Medical University Cancer Hospital, Guangxi Cancer Center)

    Nanning, Guangxi, China · Not yet recruiting

  • The First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi, China · Not yet recruiting

  • The Affiliated Cancer Hospital of Guizhou Medical University

    Guiyang, Guizhou, China · Not yet recruiting

  • Guizhou Provincial People's Hospital

    Guiyang, Guizhou, China · Not yet recruiting

  • Cangzhou Central Hospital

    Cangzhou, Hebei, China · Not yet recruiting

  • First Hospital of QinHuangDao

    Qinhuangdao, Hebei, China · Not yet recruiting

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Not yet recruiting

  • Jiamusi Cancer Hospital

    Jiamusi, Heilongjiang, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjinag, China · Not yet recruiting

  • Anyang Tumor Hospital

    Anyang, Henan, China · Not yet recruiting

  • The People's Hospital of Anyang City

    Anyang, Henan, China · Not yet recruiting

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China · Not yet recruiting

  • The First Affiliated Hospital of Xinxiang Medical University

    Xinxiang, Henan, China · Not yet recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Not yet recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Not yet recruiting

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China · Not yet recruiting

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China · Not yet recruiting

  • Xiangya Hospital Central South University

    Changsha, Hunan, China · Not yet recruiting

  • The First Affiliated Hospital of University of South China

    Hengyang, Hunan, China · Not yet recruiting

Showing 40 of 77 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.